Baxter Seeks Unusual Second 30-Month Stay On Generic Version Of Its Anesthetic Suprane
This article was originally published in The Pink Sheet Daily
Executive Summary
A redesign of the proposed generic and changes to the Paragraph IV certification could give the brand an additional six-month hold on approval of the ANDA.
You may also be interested in...
ANDA Changes May Require Paragraph IV Recertification, New 30-Month Stay
Brand litigants are beginning to argue that post-Markman application tweaks are in essence new applications eligible for new 30-month stays.
Boniva Gets A Second, Truncated 30-Month Stay
Orchid's revised patent certification against the osteoporosis drug ibandronate allows Roche to block approval until March 2012.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.